H4CBD (hydrogenated CBD, tetrahydrocannabidiol) is a cannabinoid that was first synthesized by Alexander R. Todd in 1940 derived from the catalytic hydrogenation of cannabidiol.
H2-CBD and 8,9-dihydrocannabidiol have also been referred to as "hydrogenated CBD", which may cause confusion.
Pharmacology
In 2006, it was discovered that H4CBD has a binding affinity of 145 nM at the CB1 receptor and potential anti-inflammatory effects independent of its cannabinoid receptor action. In contrast, CBD has been found to bind to the CB1 receptor as an inverse agonist/antagonist with a Ki ranging from 3.3 to 4.8 mM.
Elucidation
In 2023 H4CBD epimers were elucidated using NOESY and COSY NMR spectroscopic techniques, while the inclusion of LC-MS and SCFC were used to isolate individual diasteromers.
See also
- H2-CBD (also hydrogenated CBD)
- 8,9-Dihydrocannabidiol (one of the two components in H2CBD)
- Hexahydrocannabinol (hydrogenated THC)
- 4'-Fluorocannabidiol
- 7-Hydroxycannabidiol
- Abnormal cannabidiol
- Cannabidiol dimethyl ether
- Delta-6-cannabidiol
References
